Analyzing 9 Meters Biopharma (NASDAQ:NMTR) and DiaMedica Therapeutics (NASDAQ:DMAC)

Which is the superior business? We will compare these two companies on the basis of their institutional ownership strength, profitability, risks, earnings, analyst ratings, dividends, and valuation.

Volatility and Risk

DiaMedica Therapeutics' beta is 1.73. This means that the stock price of DiaMedica Therapeutics is 73% higher than S&P 500. This table compares DiaMedica Therapeutics's net margins with 9 Meters Biopharma, as well as their return on equity (ROE) and return on assets.

Net Margins

Return on Equity

Return on Assets

DiaMedica Therapeutics

N/A

-37.32%

-35.49%

9 Meters Biopharma

N/A

-254.13%

-119.86%

Analyst Recommendations

MarketBeat has provided a list of ratings and recommendations for DiaMedica Therapeutics, and 9 Meters Biopharma.

Sell Ratings

Hold Ratings

Buy Ratings

Strong Buy Ratings

Rating Score

DiaMedica Therapeutics

0

1

2

0

2.67

9 Meters Biopharma

0

3

3

0

2.50

DiaMedica Therapeutics has a current consensus target price at $10.00. This suggests a potential upside gain of 513.50%. 9 Meters Biopharma's consensus target price is $20.85. This suggests a potential upside gain of 2,296.55%. Analysts clearly believe that 9 Meters Biopharma has a higher potential upside than DiaMedica Therapeutics.

Value and Earnings

This table compares DiaMedica Therapeutics' gross revenue with 9 Meters Biopharma, as well as their earnings per share and valuation.

Gross Revenue

Price/Sales Ratio

Net Income

Earnings per Share

Price/Earnings ratio

DiaMedica Therapeutics

N/A

N/A

-$13.68 millions

($0.52)

-3.13

9 Meters Biopharma

N/A

N/A

-$43.77 millions

($3.24)

-0.27

DiaMedica Therapeutics trades at a lower Price-to-Earnings Ratio than 9 Meters Biopharma. This indicates that DiaMedica Therapeutics' stock is the cheaper of the two.

Institutional and Insider Ownership

Institutional investors hold 28.1% DiaMedica Therapeutics's shares. Insiders own 5.6% of DiaMedica Therapeutics. Comparatively speaking, insiders own 2.4% of the shares in 9 Meters Biopharma. Strong institutional ownership indicates that hedge funds, endowments, and large money managers believe in a company's long-term potential.

You can read more about it here:

DiaMedica Therapeutics is better than 9 Meters Biopharma in 8 out of 11 factors.

DiaMedica Therapeutics

Get Rating
)

DiaMedica Therapeutics, Inc. is a biopharmaceutical firm in clinical stages that specializes in the development and commercialization of novel recombinant protein products. It is developing the DM199 candidate product, which focuses primarily on acute ischemicstroke (AIS) as well as chronic kidney disease. Wayne Lautt founded the company on 21 January 2000. It is headquartered in Minneapolis.

Biopharma About 9 Meters

Get Rating
)

9 Meters Biopharma, Inc., a biopharmaceutical clinical-stage company, focuses on unmet gastroenterology needs. Its pipeline includes drugs for short bowel disease (SBS), celiac, and three early stage candidates for unknown rare diseases or unmet needs. MarketBeat.com offers a FREE daily email newsletter
.